Recently, bortezomib was found to inhibit right ventricular systolic pressure (RVSP), right ventricular hypertrophy index (RVHI), and percent medial wall thickness (%MT) in MCT-induced pulmonary hypertension rats in an animal model of pulmonary arterial hypertension and to increase PTEN expression by inhibiting ubiquitination of PTEN protein, thereby inhibiting the PI3K/Akt pathway and improving pulmonary artery remodeling [74]. The gene discussed is AKT1; the disease is pulmonary hypertension.